LYTIX BIOPHARMA ASA (NO0010405780) — research page
NO · no-cm-kg/MERK/NO0010405780 · as of 2026-11-06
Identity and listing
The issuer is LYTIX BIOPHARMA ASA, listed on Euronext Growth Oslo under ticker NO0010405780, with ISIN NO0010405780 and LEI 549300NXMIMRSBCDZO71. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed.
| field | value | source · read date |
|---|---|---|
| name | LYTIX BIOPHARMA ASA | source · 2026-11-06 |
| exchange | Euronext Growth Oslo | source · 2026-11-06 |
| ticker | NO0010405780 | source · 2026-11-06 |
| ISIN | NO0010405780 | source · 2026-11-06 |
| LEI | 549300NXMIMRSBCDZO71 | source · 2026-11-09 |
| security type | not on the record | |
| segment | not on the record | |
| sector | not on the record | |
| jurisdiction | not on the record | |
| status | listed | 2026-11-06 |
The disclosure read
The record holds 48 filings in the twelve months to 2026-11-06, across 39 filing days. The median gap between filing days is 5.0 days. The latest filing is dated 2026-11-06 and is of type NON-REGULATORY PRESS RELEASES, so 0 days separate it from the record date. On Euronext Growth Oslo the median is 38 filings, a median cadence gap of 7 days and a median latency of 4 days, across 85 issuers. The sector median is not on the record.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 48 | 5 | 0 |
| exchange median: Euronext Growth Oslo (85 issuers) | 38 | 7 | 4 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-06 | NON-REGULATORY PRESS RELEASES | NON-REGULATORY PRESS RELEASES | Lytix Biopharma: Invitation to the Q3 2026 Results Presentation |
| 2026-11-05 | NON-REGULATORY PRESS RELEASES | NON-REGULATORY PRESS RELEASES | Research Council of Norway awards Lytix Biopharma NOK 12 million to extend its oncolytic platform to deep-seated tumors |
| 2026-11-03 | INSIDE INFORMATION | INSIDE INFORMATION | Lytix Biopharma kunngjør at ruxotemitide i kombinasjon med pembrolizumab har nådd det primære endepunktet i fase II-studien NeoLIPA i pasienter med operabelt melanom |
| 2026-11-03 | INSIDE INFORMATION | INSIDE INFORMATION | Lytix Biopharma announces ruxotemitide plus pembrolizumab meets primary endpoint in Phase II NeoLIPA study in resectable melanoma |
| 2026-10-19 | ADDITIONAL REGULATED INFORMATION REQUIRED TO BE DISCLOSED UNDER THE LAWS OF A MEMBER STATE | ADDITIONAL REGULATED INFORMATION REQUIRED TO BE DISCLOSED UNDER THE LAWS OF A MEMBER STATE | Financial calendar |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record and its location are not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.
Events and halts
Listing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The halt flag is listed.
Orderability
The outcome is not determinable for this issuer. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/no/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.
rule acm-68000/no/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The record names 3 research houses from the issuer's investor-relations page: DNB Carnegie, Redeye Equity Research and Redeye.
| research house | analyst | source · read date |
|---|---|---|
| DNB Carnegie | Klas Palin | issuer page · 2026-11-12 |
| Redeye Equity Research | Richard Ramanius | issuer page · 2026-11-12 |
| Redeye | Richard Ramanius | issuer page · 2026-11-12 |
Open research
No openly published research notes were found on the record.
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. No issuer years are sealed, and the market's earliest sealed date and the live record start date are not on the record.
Sources
6 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://firds.esma.europa.eu/firds/ (identity.exchange)
- 10.2
- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
- 10.3
- https://mcp.no-cm-kg.ai/events/MERK/NO0010405780 (the disclosure lines)
- 10.4
- https://no.eu-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.5
- https://www.lytixbiopharma.com/investors/analyst-coverage (coverage)
- 10.6
- https://mcp.no-cm-kg.ai/record/MERK/NO0010405780 (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"NO0010405780"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:d76184d8bcc8220b.